Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

574 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Impact of immunomodulating therapy on morbidity in patients with severe sepsis.
Pittet D, Harbarth S, Suter PM, Reinhart K, Leighton A, Barker C, Macdonald F, Abraham E. Pittet D, et al. Among authors: reinhart k. Am J Respir Crit Care Med. 1999 Sep;160(3):852-7. doi: 10.1164/ajrccm.160.3.9809033. Am J Respir Crit Care Med. 1999. PMID: 10471608 Clinical Trial.
Assessment of the safety of recombinant tissue factor pathway inhibitor in patients with severe sepsis: a multicenter, randomized, placebo-controlled, single-blind, dose escalation study.
Abraham E, Reinhart K, Svoboda P, Seibert A, Olthoff D, Dal Nogare A, Postier R, Hempelmann G, Butler T, Martin E, Zwingelstein C, Percell S, Shu V, Leighton A, Creasey AA. Abraham E, et al. Among authors: reinhart k. Crit Care Med. 2001 Nov;29(11):2081-9. doi: 10.1097/00003246-200111000-00007. Crit Care Med. 2001. PMID: 11700399 Clinical Trial.
Recombinant human platelet-activating factor acetylhydrolase for treatment of severe sepsis: results of a phase III, multicenter, randomized, double-blind, placebo-controlled, clinical trial.
Opal S, Laterre PF, Abraham E, Francois B, Wittebole X, Lowry S, Dhainaut JF, Warren B, Dugernier T, Lopez A, Sanchez M, Demeyer I, Jauregui L, Lorente JA, McGee W, Reinhart K, Kljucar S, Souza S, Pribble J; Controlled Mortality Trial of Platelet-Activating Factor Acetylhydrolase in Severe Sepsis Investigators. Opal S, et al. Among authors: reinhart k. Crit Care Med. 2004 Feb;32(2):332-41. doi: 10.1097/01.CCM.0000108867.87890.6D. Crit Care Med. 2004. PMID: 14758145 Clinical Trial.
Randomized, placebo-controlled trial of the anti-tumor necrosis factor antibody fragment afelimomab in hyperinflammatory response during severe sepsis: The RAMSES Study.
Reinhart K, Menges T, Gardlund B, Harm Zwaveling J, Smithes M, Vincent JL, Tellado JM, Salgado-Remigio A, Zimlichman R, Withington S, Tschaikowsky K, Brase R, Damas P, Kupper H, Kempeni J, Eiselstein J, Kaul M. Reinhart K, et al. Crit Care Med. 2001 Apr;29(4):765-9. doi: 10.1097/00003246-200104000-00015. Crit Care Med. 2001. PMID: 11373466 Clinical Trial.
Total plasma antioxidant capacity is not always decreased in sepsis.
Pascual C, Karzai W, Meier-Hellmann A, Oberhoffer M, Horn A, Bredle D, Reinhart K. Pascual C, et al. Among authors: reinhart k. Crit Care Med. 1998 Apr;26(4):705-9. doi: 10.1097/00003246-199804000-00019. Crit Care Med. 1998. PMID: 9559608
The PIRO concept: R is for response.
Gerlach H, Dhainaut JF, Harbarth S, Reinhart K, Marshall JC, Levy M. Gerlach H, et al. Among authors: reinhart k. Crit Care. 2003 Jun;7(3):256-9. doi: 10.1186/cc2195. Epub 2003 May 8. Crit Care. 2003. PMID: 12793881 Free PMC article. No abstract available.
574 results